Division of Gastroenterology, Department of Medicine, University of California, San Francisco.
Division of Interventional Radiology, Department of Radiology, University of California, San Francisco.
Semin Liver Dis. 2021 May;41(2):117-127. doi: 10.1055/s-0040-1716565. Epub 2021 Jan 14.
The success of liver transplant (LT) for hepatocellular carcinoma (HCC) is dependent on accurate tumor staging using validated imaging criteria, and adherence to acceptable criteria based on tumor size and number. Other factors including α-fetoprotein (AFP) and response to local regional therapy (LRT) have now played a larger role in candidate selection. Tumor downstaging is defined as reduction in the size of viable tumors using LRT to meet acceptable criteria for LT, and serves as a selection tool for a subgroup of HCC with more favorable biology. The application of tumor downstaging requires a structured approach involving three key components in tumor staging-initial tumor stage and eligibility criteria, tumor viability assessment following LRT, and target tumor stage prior to LT-and incorporation of AFP into staging and treatment response assessments. In this review, we provide in-depth discussions of the key role of these staging definitions in ensuring successful outcome.
肝移植(LT)治疗肝细胞癌(HCC)的成功与否取决于使用经过验证的影像学标准进行准确的肿瘤分期,以及遵守基于肿瘤大小和数量的可接受标准。其他因素,包括甲胎蛋白(AFP)和局部区域治疗(LRT)的反应,现在在候选者选择中发挥了更大的作用。肿瘤降期是指使用 LRT 缩小有活性肿瘤的大小,以满足 LT 的可接受标准,并作为具有更有利生物学特性的 HCC 亚组的选择工具。肿瘤降期的应用需要一种结构化的方法,包括肿瘤分期中的三个关键组成部分——初始肿瘤分期和资格标准、LRT 后肿瘤活性的评估,以及 LT 前目标肿瘤分期,并将 AFP 纳入分期和治疗反应评估中。在这篇综述中,我们深入讨论了这些分期定义在确保良好结果方面的关键作用。